We sought to develop OlaR TNBC cells since olaparib has shown promising anti-tumor activity in Her2/neu-negative metastatic breast cancer patients with BRCA1 mutations (17) and is FDA approved for TNBC treatment. Here, ERBB2 is linked to breast cancer.